Quality control study on conventional metronidazole tablets available in the Iraqi market

Majeed, Saad M.; Al-Shaheen, Mohammed K.; Al-Zidan, Radhwan Nidal

doi:10.5958/0974-360x.2021.00141.4

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Majeed, et al performed a study intended to evaluate quality control parameters of various brands of metronidazole tablets that are available in the Iraqi market, they approved that all brands follow the official limitation in the test of friability and the dissolution rate of different metronidazole tablets was within 40 min and the drug released amount between (84.6%-100%). So this study indicates that all brands of metronidazole tablets presented in Iraqi pharmacies conform to the USP standards [6].…”

Section: Introductionmentioning

confidence: 59%

A Comparative Study of Quality Control Testing of Mefenamic Acid Tablets in Iraq

et al. 2022

View full text Add to dashboard Cite

Objective: This research was performed to assess the quality of different marketed tablets having mefenamic acid (500 mg). The selected tablets are produced by numerous companies and presented in the Iraqi pharmaceutical marketplace. Methods: Different batches of mefenamic acid conventional tablets were exposed for several tests of quality control. These evaluation tests include hardness, weight variation, friability, disintegration time, drug content, and drug dissolution profile. The properties of these quality tests were made conferring to the specification of USP-pharmacopeia. Results: The data of this study indicate that each tablet of mefenamic acid batches conformed to the requirement of USP pharmacopeia, the hardness was (6.87-8.06 Kg/cm2), and the drug content results were (90.666-99.214%) within USP limitation. The data of disintegration time and weight uniformity were agreeable with pharmacopeia and the in vitro release assay showed that the release of each mefenamic acid marketed tablet was highest than (80 %) in 45 min, which reproducing compliance with the USP pharmacopeia's limitation. Conclusion: From this study, it was proved that all of the marketed brands of mefenamic acid tablets meet the standard character in the USP pharmacopeia for in vitro quality control tests.

show abstract

Section: Introductionmentioning

confidence: 59%

A Comparative Study of Quality Control Testing of Mefenamic Acid Tablets in Iraq

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The results obtained in this study could have been more exact if the data of the real monetary value of the loss or its equivalent in the lack of income of the Pharmaceutical Industry caused by the lack of the products studied had been available. However, as this data is confidential, an approximation was made taking these two parameters: a-The value of sale to Pharmacies, which is not the net income value for the Pharmaceutical Industry, since it makes discounts and offers according to the quantities sold or other criteria, which depend on the marketing policy of each Industry 20 . b-The missing quantities were calculated based on the production data and they do not have a directly proportional relationship with the quantities that stopped being sold, since there could be products stored either in the Industry, or in distributors, at the time of production the lack of raw material 7 .…”

Section: Discussionmentioning

confidence: 99%

“…The implication of a computer software in these situations allows a vision of improvement, facilitating data management of all the company's resources, reducing costs and optimizing processes 20 . The aim of the present study was to provide a pharmacoeconomic analysis estimating the advantages/disadvantages of the implementation of two different software ONDANET and Enterprise Resource Planning System Software type SAP R/3 in the management processes of pharmaceutical processes.…”

mentioning

confidence: 99%

Cost-Benefit Analysis of the Implementation of an Integrated Production Software in the Raw Materials Sector of A Pharmaceutical Industry

Garcete

Olga

Marín

et al. 2022

RJPT

View full text Add to dashboard Cite

The pharmaceutical industry currently has computer systems that seek to optimize processes and allow the maximum performance of its resources through the use of computer tools. The objective of the work was to determine the costs and benefits of two different software in management of raw materials for the pharmaceutical industry. Methods: observational, descriptive, cross-sectional, study that compared ONDANET and SAP software in positive and negative costs inferred in the implementation of the tools and the benefits in terms of the profitability of the management of raw materials for the elaboration of pharmaceutical products. Results: it has been observed by using direct costs and benefits that the benefit-cost ratio of the SAP software implementation yielded a result of 15.37, whereas the ONDANET software presented a cost-benefit ratio of 0.05, which could have been demonstrated Conclusion: A widely favorable cost-benefit ratio was found for SAP Software compared to the previously used ONDANET Software, indicating that the new software used is profitable. It is desirable to periodically carry out this type of analysis to guarantee not only that the Pharmaceutical Industry has a greater profitability, without also being able to provide its products with continuity and at affordable prices for the population.

show abstract

Quality control study on conventional metronidazole tablets available in the Iraqi market

Cited by 2 publications

References 0 publications

A Comparative Study of Quality Control Testing of Mefenamic Acid Tablets in Iraq

A Comparative Study of Quality Control Testing of Mefenamic Acid Tablets in Iraq

Cost-Benefit Analysis of the Implementation of an Integrated Production Software in the Raw Materials Sector of A Pharmaceutical Industry

Contact Info

Product

Resources

About